TARA-002 demonstrates high complete response rates in BCG-naïve NMIBC patients, with 72% achieving CR and 50% maintaining it ...

Protara’s lead candidate, TARA-002, has demonstrated durable complete response (CR) rates in a single-arm Phase II trial in ...

TARA-002 achieved a 72% complete response rate in BCG-naive NMIBC patients, with durable responses at 6 and 12 months. The ...

More than three decades ago, the U.S. Food and Drug Administration (FDA) approved Bacillus Calmette-Guérin (BCG) as the first immunotherapy against cancer. And it is still used today to treat ...

Among patients with NMIBC, BCG treatment may be less effective for patients with a history of UTUC, suggesting they are at greater risk for progression. The efficacy of intravesical Bacillus ...

Mitomycin C can be a cost-effective alternative to BCG as intravesical treatment for intermediate-risk nonmuscle-invasive bladder cancer at a time when BCG is in short supply. Mitomycin C has ...

LAS VEGAS -- Event-free survival (EFS) in high-risk non-muscle invasive bladder cancer (NMIBC) improved significantly when patients received the PD-1 inhibitor sasanlimab in addition to bacillus ...

NMIBC treatment varies by tumor stage, grade, and prior therapies, with high-risk cases often requiring radical cystectomy. Bladder-preserving approaches include intravesical therapies like BCG, ...

You've been diagnosed with bladder cancer that has not invaded the muscle layer -- i.e., non-muscle invasive bladder cancer (NMIBC), also called superficial bladder cancer. Although the cure rate with ...

Dino Carlone was frightened when he was diagnosed with bladder cancer three years ago, but his spirits were buoyed when he learned that he could get help from a highly effective drug with a great ...

PARSIPPANY, N.J.--(BUSINESS WIRE)--Ferring Pharmaceuticals today announced the final 60-month follow-up data from the Phase 3 study of ADSTILADRIN ® (nadofaragene firadenovec-vncg) were presented at ...